

Torrent Pharma's Dahej Plant receives EIR from US FDA

March 18th, 2016

Torrent Pharma, one of the leading pharma companies of the country has successfully obtained the Establishment Inspection Report (EIR) from USFDA for its plant located at Dahej SEZ, in Gujarat. Prior to this approval, the Plant has also received approval from EU Germany. It was set up to cater mainly to the regulated international markets such as US, Brazil, Germany etc.

With the approval, this plant is now the 3rd plant of Torrent Pharma to receive US FDA approval, out of its 5 manufacturing units. The company's other US FDA approved plant include the Plant at Indrad, Gujarat and Pithampur (Indore), MP.

The plant is spread across 70 acres with a built up area of around 97000 sq. mtr. Phase I has an installed capacity of about 7,500 million tablets / capsules and 25 MT API per annum. Construction of Phase II will commence soon and once commissioned the total capacity will increase to about 14,000 million tablets / capsules and 80 MT API per year.

About Torrent Pharma

Torrent Pharma, with annual revenues of almost Rs. 4700 crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset). Torrent has a full equipped Research Centre, employing almost 600 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's existing manufacturing plants located at Indrad, Baddi, Sikkim, Indore & Dahej have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.